The purpose of the study is to assess the sensibility of the ISL questionnaire.

Condition	Intervention	Phase
Erectile Dysfunction	Drug: sildenafil	Phase IV

Further study details as provided by Pfizer:

Primary Outcomes: Treatment responsiveness of a new quality of sexual life questionnaire for female partners of men with erectile dysfunction.
Secondary Outcomes: The correlation between ED patients'''' partner quality of sexual life changes and patient''''s efficacy measures and these changes and patient reported outcomes of self-esteem
Expected Total Enrollment:  120

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

ED patient must:

• Be male, ³ 18 years of age with no upper age limit;
• Have a documented clinical diagnosis of erectile dysfunction confirmed by an Erectile Function (IIEF) score £ 25. Erectile dysfunction is defined as "the inability to achieve and/or maintain an erection of the penis sufficient to permit satisfactory sexual performance" (Impotence-NIH Consensus Conference, JAMA 1993, 270: 83-90);
• Have a stable female partner for at least 6 months prior to screening.

Exclusion Criteria:

• Have a known hypersensitivity to sildenafil or any component of the study medication; medical history of treatment-related intolerable side effects to sildenafil
• Be currently prescribed, taking and/or likely to be treated with nitrates or nitric oxide donors in any form on either a regular or intermittent basis;;

Please refer to this study by ClinicalTrials.gov identifier  NCT00245596

Study chairs or principal investigators

Pfizer CT.gov Call Center,  Study Director,  Pfizer   

Study ID Numbers:  A1481210
Last Updated:  December 8, 2005
Record first received:  October 27, 2005
ClinicalTrials.gov Identifier:  NCT00245596
Health Authority: France: AFSSAPS
ClinicalTrials.gov processed this record on 2006-01-10